RenovoRx
PublicRenovoRx is now publicly traded
The data on this page reflects RenovoRx's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Private Placement
Apr 9, 2026
Total Funding Raised
$10M
Company Overview
RenovoRx, Inc. is a clinical-stage biopharmaceutical company that develops precision oncology therapies. The company's proprietary Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed for the targeted delivery of therapeutic agents to solid tumors, aiming to increase efficacy while minimizing systemic toxicities. Its lead product candidate, RenovoGem, is a drug-device combination product being evaluated in a Phase III clinical trial for the treatment of locally advanced pancreatic cancer. The company is also commercializing its FDA-cleared RenovoCath delivery device as a standalone product, with first commercial orders received in late 2024. RenovoRx is a public company listed on the Nasdaq under the ticker RNXT.
AI Layer
Non-AI
Keywords
RenovoRx Comparables
Compare RenovoRx with similar companies based on industry and business-model similarity.
RenovoRx Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | Apr 9, 2026 |
RenovoRx Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Pathfinder Asset Management Limited | Private Placement |
| Transcend Partners | Private Placement |
| Bleichroeder | Private Placement |
RenovoRx Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |